07:27 AM EDT, 09/19/2025 (MT Newswires) -- Merck ( MRK ) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted two positive opinions for Keytruda.

One opinion recommends the approval of a new subcutaneous route of administration and a new pharmaceutical form for Keytruda, while the other recommends approval of a new indication in locally advanced head and neck squamous cell carcinoma, a type of cancer.

The company said the recommendations will now be reviewed by the European Commission for marketing authorization in the EU, Iceland, Liechtenstein and Norway, with final decisions expected in Q4.